Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FOLD

Fold (NASDAQ:FLD) reported a difficult first quarter of fiscal 2026, with management citing a broad pullback in Bitcoin prices and related pressure on customer activity across the industry. On the company’s May 12 earnings call, Chairman and CEO Will Reeves said lower Bitcoin prices weighed on tran

MarketBeat

Is it a gaming handheld? Is it a PC? It's both – this Steam Deck rival could bring foldables to gaming

Lenovo Legion Go Fold could be the Windows PC foldable we've been waiting for

I’ve Been Using the Fold Reformer Pilates Machine At Home for 3 Months – and It's So Good, I Swear I'll Never Go Back

It’s been the best postpartum exercise decision *ever*.

Marie Claire

From analysis to the latest developments in health,
read the most diverse news in one place.

My stepmom is obsessed with reformer Pilates — she's spent hours and hours with the FOLD Reformer machine, and this is the verdict

The Original FOLD Reformer bed has taken the at-home Pilates industry by storm and offers a studio experience in your own home. We put it to the test for six weeks, and this is what we think.

Tom’s Guide

I tried the at-home Pilates reformer that rivals studio classes, and it didn’t disappoint

The FOLD reformer has become popular for its elegant design and premium features

The best techno clubs in London, from Corsica Studios to XOYO

From FOLD to Venue MOT Unit 18 and The Cause, Arielle Domb names the top venues to hang out in

Evening Standard

3 Emerging Biotech Firms Pioneering Next-Gen Therapies

The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries. Thus, investing in fundamentally stable biotech stocks, Veracyte (VCYT), Amicus Therapeutics (FOLD), and Harmony Biosciences (HRMY), could be one way to capitalize on the industry's prospects. Read more….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

10 must-have fitness gadgets that will transform your health this year

From a mattress topper that will transform your sleep to an at-home Reformer Pilates machine, Jessica Salter on the tech we will all be coveting this year

Evening Standard

Nowhere to go on New Year's Eve? Our pick of the best London clubs to hit on the last night of 2024

Still haven’t organised a solid New Year’s Eve Plan? Here’s a handpicked list of the best club nights to ring in 2025

Evening Standard

3 High-Growth Biotech Stocks to Watch

Amid the growing innovations, emphasis on enhanced treatment alternatives, and rapid AI adoption, the biotechnology industry is poised for solid long-term growth. Thus, investors could consider adding high-growth biotech stocks MannKind (MNKD), Amicus Therapeutics (FOLD), and Esperion Therapeutics (ESPR) to their watchlist. Continue reading.

StockNews.com

Ditch the gym – the FOLD Reformer turns your home into a fully-fledged Pilates studio!

Conference coral — Akshata Murty’s £875 suit for Rishi Sunak’s speech

The Prime Minster’s wife made sure not to fade into the background on the day of hubsand Sunak’s speech

Evening Standard

Moderna (MRNA) and 2 More Biotech Stocks That Are Worth Watching

Growing demand for personalized medicines and rising adoption of machine learning tools are expected to boost the biotech industry. Therefore, it could be wise to watch fundamentally strong biotech stocks Moderna (MRNA), Amicus Therapeutics (FOLD), and Entrada Therapeutics (TRDA). Read more.

StockNews.com

Which of These 3 Biotech Stocks Are a Buy, Sell, or Hold?

Advanced medical technologies and the pivotal role of technology in drug development are poised to drive significant growth in the biotech industry. Against this backdrop, should you buy, sell or hold biotech stocks Moderna (MRNA), MacroGenics (MGNX), and Amicus Therapeutics (FOLD)? Let’s find out….

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Moderna (MRNA) vs. Amicus Therapeutics (FOLD): Which Biotech Stock Should You Add to Your Portfolio?

Healthcare is considered a reliable defensive sector. So, amid the current uncertain economic landscape, let's determine the more favorable investment option between two prominent pharmaceutical companies, Moderna (MRNA) and Amicus Therapeutics (FOLD). Keep reading.

StockNews.com

3 Top Biotech Stocks to Purchase Right Away

The ever-rising demand for quality healthcare is expected to benefit the biotech industry. Moreover, favorable government initiatives to boost domestic biotech research and production should boost the industry’s prospects. Therefore, it could be wise to buy fundamentally strong biotech stocks Shionogi & Co. (SGIOY), Amicus Therapeutics (FOLD), and Entrada Therapeutics…

StockNews.com

Invest in These 3 Biotech Stocks Today

With the biotech industry experiencing significant growth due to the increasing demand for healthcare solutions, fundamentally sound stocks such as Amicus Therapeutics (FOLD), POINT Biopharma Global (PNT), and Precision BioSciences (DTIL) might have the potential to provide substantial returns for investors and could be valuable portfolio additions this month. Learn…

StockNews.com

Top 3 Biotech Stocks with Breakout Potential

The biotech industry is well-positioned to witness significant growth due to technological advancements and government spending. Moreover, given the sector’s defensive nature, biotech stocks Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), and Harmony Biosciences (HRMY) might be solid buys in 2023. Read on.

Get all your
news in one place.

100's of premium titles.
One news app.

Laptop

Google Pixel Fold hands-on: Thinnest foldable ever

The Pixel Fold is Google's first foray into the foldable space brings an incredibly slim design, beyond all-day battery life and Google's excellent camera at an eye-watering price.

StockNews.com

2 Most Promising Biotech Stocks to Buy

Given the breakthrough developments and government initiatives, the biotech industry is well-positioned to grow steadily. Therefore, fundamentally strong biotech stocks Amicus Therapeutics (FOLD) and POINT Biopharma (PNT) could be worth buying now. Read on.

StockNews.com

Healthcare Innovation: 3 Biotech Stocks to Watch in May 2023

As the biotech sector is expanding rapidly in response to the growing need for healthcare solutions, fundamentally strong biotech stocks Amicus Therapeutics (FOLD), Ardelyx (ARDX), and Genfit S.A. (GNFT) have the potential to generate substantial returns for investors. Hence, these stocks could be solid watchlist additions this month. Read more….

Manchester Evening News

This hidden riverside village is one of Greater Manchester’s best kept secrets

Marple Bridge is at the edge of the Peak District and is regarded as one of the best spots in the region to explore the great outdoors from

StockNews.com

3 Biotech Stocks to Buy and Hold for the Next 20 Years

The biotech industry is well-positioned for long-term growth owing to strong demand and continued breakthroughs. Furthermore, favorable government funding should boost the industry’s growth. Hence, it could be wise to buy and hold fundamentally sound biotech stocks Amgen (AMGN), Biogen (BIIB), and Amicus Therapeutics (FOLD) for the next two decades.…

Evening Standard

Clubbing in London: The best nights out in the capital this autumn and winter

From blockbuster stadium shows to intimate raves, here’s where to have it large

Benzinga

Short Volatility Alert: Amicus Therapeutics, Inc.

On Tuesday, shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) experienced volatile short activity. After the activity, the stock price went up +5.67% to $9.88. The overall sentiment for FOLD has been Bearish.

1 2

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.